Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
It’s not often that a company with the scale and…
Sell
31
HRMY Quote, Financials, Valuation and Earnings
Last price:
$34.26
Seasonality move
:
-6.84%
Day range:
$33.48 - $34.97
52-week range:
$28.14 - $41.61
Dividend yield:
0%
P/E ratio:
16.25x
P/S ratio:
2.92x
P/B ratio:
3.28x
Volume:
2.9M
Avg. volume:
580.3K
1-year change:
6.99%
Market cap:
$2B
Revenue:
$582M
EPS (TTM):
$2.11
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
HRMY
Harmony Biosciences Holdings
|
$184.1M | $0.88 | 17.91% | 84.23% | $53.88 |
|
ARWR
Arrowhead Pharmaceuticals
|
$58.9M | -$0.92 | 543.01% | -12.15% | $47.50 |
|
DYN
Dyne Therapeutics
|
-- | -$0.71 | -- | -21.38% | -- |
|
EYPT
EyePoint Pharmaceuticals
|
$10.4M | -$0.54 | -25.19% | -53.26% | $33.45 |
|
INCY
Incyte
|
$1.1B | $1.09 | 12.94% | 74.92% | $79.38 |
|
REGN
Regeneron Pharmaceuticals
|
$3.7B | $11.70 | 9.55% | 7.9% | $1,053.08 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
HRMY
Harmony Biosciences Holdings
|
$34.28 | $53.88 | $2B | 16.25x | $0.00 | 0% | 2.92x |
|
ARWR
Arrowhead Pharmaceuticals
|
$19.47 | $47.50 | $2.4B | -- | $0.00 | 0% | 12.83x |
|
DYN
Dyne Therapeutics
|
$23.99 | -- | $2.4B | -- | $0.00 | 0% | -- |
|
EYPT
EyePoint Pharmaceuticals
|
$7.12 | $33.45 | $485.9M | -- | $0.00 | 0% | 7.90x |
|
INCY
Incyte
|
$68.91 | $79.38 | $13.3B | 492.21x | $0.00 | 0% | 3.67x |
|
REGN
Regeneron Pharmaceuticals
|
$701.85 | $1,053.08 | $77.1B | 17.37x | $0.00 | 0% | 5.83x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
HRMY
Harmony Biosciences Holdings
|
23.45% | 1.657 | 8.02% | 3.05x |
|
ARWR
Arrowhead Pharmaceuticals
|
-- | 3.960 | -- | -- |
|
DYN
Dyne Therapeutics
|
-- | 3.180 | -- | -- |
|
EYPT
EyePoint Pharmaceuticals
|
-- | 2.791 | -- | 5.21x |
|
INCY
Incyte
|
-- | 0.831 | -- | 1.69x |
|
REGN
Regeneron Pharmaceuticals
|
6.34% | 1.460 | 1.71% | 4.34x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
HRMY
Harmony Biosciences Holdings
|
$143.3M | $61.7M | 17.28% | 23.59% | 35.76% | $70.5M |
|
ARWR
Arrowhead Pharmaceuticals
|
-- | -$162.2M | -- | -- | -- | -$161.5M |
|
DYN
Dyne Therapeutics
|
-- | -$105.7M | -- | -- | -- | -$74.9M |
|
EYPT
EyePoint Pharmaceuticals
|
$9.8M | -$32.7M | -50.67% | -50.67% | -278.99% | -$40.6M |
|
INCY
Incyte
|
$1.1B | $169.5M | 0.75% | 0.75% | 13.82% | $293.2M |
|
REGN
Regeneron Pharmaceuticals
|
$3.2B | $1.2B | 16.02% | 17.19% | 40.5% | $1B |
Harmony Biosciences Holdings vs. Competitors
-
Which has Higher Returns HRMY or ARWR?
Arrowhead Pharmaceuticals has a net margin of 24.78% compared to Harmony Biosciences Holdings's net margin of --. Harmony Biosciences Holdings's return on equity of 23.59% beat Arrowhead Pharmaceuticals's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital HRMYHarmony Biosciences Holdings77.01% $0.79 $779.7M ARWRArrowhead Pharmaceuticals-- -$1.37 -- -
What do Analysts Say About HRMY or ARWR?
Harmony Biosciences Holdings has a consensus price target of $53.88, signalling upside risk potential of 57.16%. On the other hand Arrowhead Pharmaceuticals has an analysts' consensus of $47.50 which suggests that it could grow by 144.03%. Given that Arrowhead Pharmaceuticals has higher upside potential than Harmony Biosciences Holdings, analysts believe Arrowhead Pharmaceuticals is more attractive than Harmony Biosciences Holdings.
Company Buy Ratings Hold Ratings Sell Ratings HRMYHarmony Biosciences Holdings4 0 0 ARWRArrowhead Pharmaceuticals7 5 0 -
Is HRMY or ARWR More Risky?
Harmony Biosciences Holdings has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Arrowhead Pharmaceuticals has a beta of 0.906, suggesting its less volatile than the S&P 500 by 9.418%.
-
Which is a Better Dividend Stock HRMY or ARWR?
Harmony Biosciences Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Arrowhead Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Harmony Biosciences Holdings pays -- of its earnings as a dividend. Arrowhead Pharmaceuticals pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios HRMY or ARWR?
Harmony Biosciences Holdings quarterly revenues are $186M, which are larger than Arrowhead Pharmaceuticals quarterly revenues of --. Harmony Biosciences Holdings's net income of $46.1M is higher than Arrowhead Pharmaceuticals's net income of -$170.5M. Notably, Harmony Biosciences Holdings's price-to-earnings ratio is 16.25x while Arrowhead Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Harmony Biosciences Holdings is 2.92x versus 12.83x for Arrowhead Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HRMYHarmony Biosciences Holdings2.92x 16.25x $186M $46.1M ARWRArrowhead Pharmaceuticals12.83x -- -- -$170.5M
-
Which has Higher Returns HRMY or DYN?
Dyne Therapeutics has a net margin of 24.78% compared to Harmony Biosciences Holdings's net margin of --. Harmony Biosciences Holdings's return on equity of 23.59% beat Dyne Therapeutics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital HRMYHarmony Biosciences Holdings77.01% $0.79 $779.7M DYNDyne Therapeutics-- -$0.96 -- -
What do Analysts Say About HRMY or DYN?
Harmony Biosciences Holdings has a consensus price target of $53.88, signalling upside risk potential of 57.16%. On the other hand Dyne Therapeutics has an analysts' consensus of -- which suggests that it could grow by 110.16%. Given that Dyne Therapeutics has higher upside potential than Harmony Biosciences Holdings, analysts believe Dyne Therapeutics is more attractive than Harmony Biosciences Holdings.
Company Buy Ratings Hold Ratings Sell Ratings HRMYHarmony Biosciences Holdings4 0 0 DYNDyne Therapeutics0 0 0 -
Is HRMY or DYN More Risky?
Harmony Biosciences Holdings has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Dyne Therapeutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock HRMY or DYN?
Harmony Biosciences Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Dyne Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Harmony Biosciences Holdings pays -- of its earnings as a dividend. Dyne Therapeutics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios HRMY or DYN?
Harmony Biosciences Holdings quarterly revenues are $186M, which are larger than Dyne Therapeutics quarterly revenues of --. Harmony Biosciences Holdings's net income of $46.1M is higher than Dyne Therapeutics's net income of -$97.1M. Notably, Harmony Biosciences Holdings's price-to-earnings ratio is 16.25x while Dyne Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Harmony Biosciences Holdings is 2.92x versus -- for Dyne Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HRMYHarmony Biosciences Holdings2.92x 16.25x $186M $46.1M DYNDyne Therapeutics-- -- -- -$97.1M
-
Which has Higher Returns HRMY or EYPT?
EyePoint Pharmaceuticals has a net margin of 24.78% compared to Harmony Biosciences Holdings's net margin of -278.99%. Harmony Biosciences Holdings's return on equity of 23.59% beat EyePoint Pharmaceuticals's return on equity of -50.67%.
Company Gross Margin Earnings Per Share Invested Capital HRMYHarmony Biosciences Holdings77.01% $0.79 $779.7M EYPTEyePoint Pharmaceuticals93.01% -$0.54 $218.7M -
What do Analysts Say About HRMY or EYPT?
Harmony Biosciences Holdings has a consensus price target of $53.88, signalling upside risk potential of 57.16%. On the other hand EyePoint Pharmaceuticals has an analysts' consensus of $33.45 which suggests that it could grow by 369.87%. Given that EyePoint Pharmaceuticals has higher upside potential than Harmony Biosciences Holdings, analysts believe EyePoint Pharmaceuticals is more attractive than Harmony Biosciences Holdings.
Company Buy Ratings Hold Ratings Sell Ratings HRMYHarmony Biosciences Holdings4 0 0 EYPTEyePoint Pharmaceuticals8 0 0 -
Is HRMY or EYPT More Risky?
Harmony Biosciences Holdings has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison EyePoint Pharmaceuticals has a beta of 1.455, suggesting its more volatile than the S&P 500 by 45.456%.
-
Which is a Better Dividend Stock HRMY or EYPT?
Harmony Biosciences Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. EyePoint Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Harmony Biosciences Holdings pays -- of its earnings as a dividend. EyePoint Pharmaceuticals pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios HRMY or EYPT?
Harmony Biosciences Holdings quarterly revenues are $186M, which are larger than EyePoint Pharmaceuticals quarterly revenues of $10.5M. Harmony Biosciences Holdings's net income of $46.1M is higher than EyePoint Pharmaceuticals's net income of -$29.4M. Notably, Harmony Biosciences Holdings's price-to-earnings ratio is 16.25x while EyePoint Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Harmony Biosciences Holdings is 2.92x versus 7.90x for EyePoint Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HRMYHarmony Biosciences Holdings2.92x 16.25x $186M $46.1M EYPTEyePoint Pharmaceuticals7.90x -- $10.5M -$29.4M
-
Which has Higher Returns HRMY or INCY?
Incyte has a net margin of 24.78% compared to Harmony Biosciences Holdings's net margin of 9.36%. Harmony Biosciences Holdings's return on equity of 23.59% beat Incyte's return on equity of 0.75%.
Company Gross Margin Earnings Per Share Invested Capital HRMYHarmony Biosciences Holdings77.01% $0.79 $779.7M INCYIncyte92.44% $0.54 $3.2B -
What do Analysts Say About HRMY or INCY?
Harmony Biosciences Holdings has a consensus price target of $53.88, signalling upside risk potential of 57.16%. On the other hand Incyte has an analysts' consensus of $79.38 which suggests that it could grow by 15.19%. Given that Harmony Biosciences Holdings has higher upside potential than Incyte, analysts believe Harmony Biosciences Holdings is more attractive than Incyte.
Company Buy Ratings Hold Ratings Sell Ratings HRMYHarmony Biosciences Holdings4 0 0 INCYIncyte10 14 0 -
Is HRMY or INCY More Risky?
Harmony Biosciences Holdings has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Incyte has a beta of 0.686, suggesting its less volatile than the S&P 500 by 31.381%.
-
Which is a Better Dividend Stock HRMY or INCY?
Harmony Biosciences Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Incyte offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Harmony Biosciences Holdings pays -- of its earnings as a dividend. Incyte pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios HRMY or INCY?
Harmony Biosciences Holdings quarterly revenues are $186M, which are smaller than Incyte quarterly revenues of $1.1B. Harmony Biosciences Holdings's net income of $46.1M is lower than Incyte's net income of $106.5M. Notably, Harmony Biosciences Holdings's price-to-earnings ratio is 16.25x while Incyte's PE ratio is 492.21x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Harmony Biosciences Holdings is 2.92x versus 3.67x for Incyte. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HRMYHarmony Biosciences Holdings2.92x 16.25x $186M $46.1M INCYIncyte3.67x 492.21x $1.1B $106.5M
-
Which has Higher Returns HRMY or REGN?
Regeneron Pharmaceuticals has a net margin of 24.78% compared to Harmony Biosciences Holdings's net margin of 36.03%. Harmony Biosciences Holdings's return on equity of 23.59% beat Regeneron Pharmaceuticals's return on equity of 17.19%.
Company Gross Margin Earnings Per Share Invested Capital HRMYHarmony Biosciences Holdings77.01% $0.79 $779.7M REGNRegeneron Pharmaceuticals86.8% $11.54 $31.3B -
What do Analysts Say About HRMY or REGN?
Harmony Biosciences Holdings has a consensus price target of $53.88, signalling upside risk potential of 57.16%. On the other hand Regeneron Pharmaceuticals has an analysts' consensus of $1,053.08 which suggests that it could grow by 50.04%. Given that Harmony Biosciences Holdings has higher upside potential than Regeneron Pharmaceuticals, analysts believe Harmony Biosciences Holdings is more attractive than Regeneron Pharmaceuticals.
Company Buy Ratings Hold Ratings Sell Ratings HRMYHarmony Biosciences Holdings4 0 0 REGNRegeneron Pharmaceuticals12 6 0 -
Is HRMY or REGN More Risky?
Harmony Biosciences Holdings has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals has a beta of 0.084, suggesting its less volatile than the S&P 500 by 91.622%.
-
Which is a Better Dividend Stock HRMY or REGN?
Harmony Biosciences Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Harmony Biosciences Holdings pays -- of its earnings as a dividend. Regeneron Pharmaceuticals pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios HRMY or REGN?
Harmony Biosciences Holdings quarterly revenues are $186M, which are smaller than Regeneron Pharmaceuticals quarterly revenues of $3.7B. Harmony Biosciences Holdings's net income of $46.1M is lower than Regeneron Pharmaceuticals's net income of $1.3B. Notably, Harmony Biosciences Holdings's price-to-earnings ratio is 16.25x while Regeneron Pharmaceuticals's PE ratio is 17.37x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Harmony Biosciences Holdings is 2.92x versus 5.83x for Regeneron Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HRMYHarmony Biosciences Holdings2.92x 16.25x $186M $46.1M REGNRegeneron Pharmaceuticals5.83x 17.37x $3.7B $1.3B
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Tyson Foods Stock Bounce Back?
Tyson Foods, Inc. (NYSE:TSN) is one of the biggest food…
Will Iovance Biotherapeutics Stock Bounce Back?
Iovance Biotherapeutics (NASDAQ:IOVA) is a fledgling pharmaceutical company that specializes…
Stock Ideas
Buy
64
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 42x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 113x
Buy
55
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Buy
61
QMCO alert for Dec 21
Quantum [QMCO] is up 26.28% over the past day.
Sell
46
NUKK alert for Dec 21
Nukkleus [NUKK] is down 22.94% over the past day.
Sell
1
IIPR alert for Dec 21
Innovative Industrial Properties [IIPR] is down 22.7% over the past day.
